Validation of LC–MS/MS methods for the determination of mirabegron and eight metabolites in human plasma in a paediatric population
Authors:
Open Access
- 1 April 2019
- journal article
- research article
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 167, 155-160
Abstract
No abstract availableKeywords
Funding Information
- Astellas
This publication has 6 references indexed in Scilit:
- Diagnosis and Treatment of Overactive Bladder (Non-Neurogenic) in Adults: AUA/SUFU Guideline AmendmentJournal of Urology, 2015
- Do we need a new definition of the overactive bladder syndrome? ICI-RS 2013Neurourology and Urodynamics, 2014
- Single dose pharmacokinetics and absolute bioavailability of mirabegron, a ?3-adrenoceptor agonist for treatment of overactive bladderInt. Journal of Clinical Pharmacology and Therapeutics, 2012
- Pharmacokinetic Properties of Mirabegron, a β3-Adrenoceptor Agonist: Results From Two Phase I, Randomized, Multiple-Dose Studies in Healthy Young and Elderly Men and WomenClinical Therapeutics, 2012
- Identification of human cytochrome P450 isoforms and esterases involved in the metabolism of mirabegron, a potent and selective β3-adrenoceptor agonistXenobiotica, 2012
- Absorption, Metabolism and Excretion of [14C]Mirabegron (YM178), a Potent and Selective β3-Adrenoceptor Agonist, after Oral Administration to Healthy Male VolunteersDrug Metabolism and Disposition, 2012